{"schema_version":"secwatch.filing_event.v1","accession":"0001638833-22-000132","form_type":"8-K","ticker":"SGRY","cik":"0001638833","company_name":"Surgery Partners, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.527702+00:00","generated_at":"2026-06-22T03:48:56.188759+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Surgery Partners Q3 revenue +11% to $620.6M, Adj EBITDA $96.2M, reaffirms FY guidance","bullets":["Revenue $620.6M (+11.0% YoY); same-facility revenue +5.1% (cases +3.3%, rev/case +1.8%).","Net loss $25.0M vs $22.9M loss; Adjusted EBITDA $96.2M (+26% YoY); margin 15.5% (+180bps).","Reaffirms FY2022 Adj EBITDA $375M-$385M; revenue $2.5-$2.55B.","YTD deployed $240M on acquisitions (12 facilities) at sub-8x EBITDA; added 150+ physicians.","Liquidity ~$500M ($154.8M cash + $342M revolver capacity); net debt/EBITDA 6.0x."],"urls":{"canonical":"https://secwatch.observer/filing/0001638833-22-000132","json":"https://secwatch.observer/filing/0001638833-22-000132.json","markdown":"https://secwatch.observer/filing/0001638833-22-000132.md","text":"https://secwatch.observer/filing/0001638833-22-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/0001638833-22-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/sgry-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:48:56.188759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9022d5e3698c1e529ab4f73241f5410332e8c9e2","claim":"Surgery Partners, Inc. reported Full year 2022 results: revenue $2.5 billion to $2.55 billion. Guidance reaffirmed.","evidence_excerpt":"The Company reaffirms projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/0001638833-22-000132-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year 2022"},{"label":"Revenue","value":"$2.5 billion to $2.55 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c666d3ebc4fc2f83f1bd069589616830747dad58","claim":"Surgery Partners, Inc. reported Third quarter ended September 30, 2022 results: revenue $620.6 million, net income -$25.0 million.","evidence_excerpt":"Revenue for the third quarter of 2022 increased 11.0% to $620.6 million from $559.2 million for the third quarter of 2021. Same-facility revenues for the third quarter of 2022 increased 5.1% from the same period last year, with an increase in revenue per case of 1.8% and an increase in same-facility cases of 3.3%. For the third quarter of 2022, the Company’s net 1 loss attributable to common stockholders and Adjusted EBITDA was $25.0 million and $96.2 million, respectively, compared to $22.9 million and $76.4 million, respectively, for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/0001638833-22-000132-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third quarter ended September 30, 2022"},{"label":"Revenue","value":"$620.6 million"},{"label":"Net income","value":"-$25.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}